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Endogenous inhibitory mediators such as prostacyclin
and nitric oxide keep platelet activation under tight con-
trol through the corresponding cGMP and cAMP signaling
pathways. Intracellular levels of cAMP and cGMP are reg-
ulated by cyclic-nucleotide phosphodiesterases (PDEs).
PDE3A (also known as cGMP-inhibited cAMP PDE) and
PDE5 (cGMP specific PDE) are major cAMP-hydrolyzing
and cGMP hydrolyzing PDEs expressed in platelets. Plate-
let PDE3A has been found to be phosphorylated and acti-
vated by PKA [1] and PDE5 by PKG [2]. Here we report
that in human platelets PKG can also phosphorylate
PDE3A, providing an additional cross-talk between cGMP
and cAMP signaling.
In non-treated human platelets PDE3A has been identi-
fied as a band with an apparent molecular weight of 110
kDa. Treatment of human platelets with SNP resulted in a
time dependent mobility shift in SDS-PAGE. ODQ com-
pletely blocked the change in mobility for PDE3A as well
as PKG induced phosphorylation of PDE5. Two PKG acti-
vators (8-Br-cGMP and 8-pCPT-cGMP) produced similar
changes in PDE3A mobility, which were also parallel with
changes in PDE5 phosphorylation. The PKG inhibitor
(Rp-8-Br-PET-cGMPS) prevented phosphorylation of
both PDE3A and PDE5 induced by 8-pCPT-cGMP.
In vitro phosphorylation of human platelet PDE3A by the
addition of exogenous PKG produced the same shift in
mobility of PDE3A in SDS-PADE as all experiments per-
formed on intact platelets. Phosphorylation of PDE3A by
PKA in vitro or in forskolin-treated platelets also resulted
in changes in its mobility.
In platelets application of cGMP-elevating agents leads
not only to higher intracellular cGMP concentration, but
also to higher cAMP concentration through direct inhibi-
tion of PDE3A by cGMP. Our data provide evidence that
PKG is able to control the duration of both cAMP and
cGMP signalling by simultaneous phosphorylation of
both PDE3A and PDE5 in human platelets.
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